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OBJECTIVES: To determine in Italy the incremental cost per life
year saved (ICLYS) of clopidogrel versus ASA in secondary pre-
vention of ischemic stroke (IS), myocardial infarction (MI), or
vascular death in four high risk atherothrombotic populations:
1) with prior IS or MI to index event; 2) treated for hypercho-
lesterolemia and/or with diabetes; 3) polyvascular; and 4) with
prior cardiac surgery (CABG). METHODS: The economic
analysis was performed from the Italian Health Care System per-
spective using only direct medical costs. A Markov model
designed with 7 clinical states calculated ICLYS as the cost
needed to achieve an extra life year with a two-year treatment
with clopidogrel compared to ASA, over a lifetime horizon. The
model combined clinical outcomes from the CAPRIE trial data-
base and survival data derived from the Saskatchewan database.
The costing of events, including acute care and two-year follow-
up, was evaluated using ofﬁcial data for DRGs, tariffs and/or
charges (physicians fees, examinations, lab tests). A discount rate
of 3% was applied to costs and lifetime effects. RESULTS: Per
1000 patients treated with clopidogrel the additional ischemic
events avoided and the gain in life years were: 27 events and 119
years in prior IS or MI patients; 28 events and 130 years in
hypercholesterolemic and/or diabetic patients; 24 events and 138
years in polyvascular patients; 82 events and 474 years in prior
CABG patients. The ICLYS of clopidogrel compared to ASA
were 9055€ in prior IS or MI group, 7880€ in patients treated
for hypercholesterolemia and/or diabetes, 8216€ in polyvascular
patients and 2001€ in CABG patients. Results were robust under
a wide variation of key parameters. CONCLUSION: In Italy a
two-year treatment with Clopidogrel as an alternative to ASA is
a cost-effective strategy in secondary prevention of ischemic fatal
and non-fatal events for high-risk atherothrombotic patients.
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OBJECTIVES: The CURE study has demonstrated that treat-
ment strategy involving clopidogrel plus aspirin, comparing to
aspirin alone, signiﬁcantly reduced the risk of cardiovascular
death, myocardial infarction and stroke in patients with ACS
without ST-segment elevation. For every 1000 patients treated
with clopidogrel there were 20 less strokes, myocardial infarc-
tions or cardiovascular deaths (crude NNT = 50). The purpose
of the present study was to evaluate cost-effectiveness of clopi-
dogrel in Poland based on CURE trial efﬁcacy data. METHODS:
Data on resource use i.e. hospitalizations, medical procedures,
concomitant medications and study drug were derived from case
report form of CURE trial. Unit costs were calculated using
drugs retail prices and medical procedures tariffs contracted by
National Health Found. Cost-effectiveness was expressed as cost
per cardiovascular event avoided. The time horizon was the
mean study duration of 9 months. All costs are expressed in
EURO and EURO-PPP (1EURO = 2.08 PLN’ PPP2003).
RESULTS: Mean direct treatment cost per patient was higher in
clopidogrel than control group (2395 and 1931€; 5074€, and
4100€, PPP, respectively). The observed difference was attribut-
able mostly to a higher acquisition cost of clopidogrel. The mean
cost of initial and subsequent hospitalizations (including study
drug) was reduced for clopidogrel group by 18 and 24€, 40, and
53€-PPP, respectively. The estimated incremental cost per event
avoided amounted to 23,076€ and 48,497 EURO-PPP. CON-
CLUSIONS: Treatment with clopidogrel resulted in reduction of
initial and subsequent hospitalizations costs. The cost per event
avoided with clopidogrel in patients with ACS is consistent with
results from other countries and compares well to other treat-
ment strategies in patients with cardiovascular disease.
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OBJECTIVES: Results from the PCI-CURE trial demonstrated
that treatment strategy involving clopidogrel plus aspirin, com-
paring to aspirin alone, signiﬁcantly reduced the risk of cardio-
vascular death, myocardial infarction and stroke in patients with
acute coronary syndromes (ACS) without ST-segment elevation
undergoing percutaneous coronary interventions (PCI). The
purpose of the present study was to evaluate cost per event
avoided in the PCI subgroup of CURE trial, in Poland.
METHODS: Data on resource use, i.e. hospitalizations, medical
procedures, concomitant medications and study drug were
derived from case report form of PCI-CURE trial. Unit costs
were calculated using drugs retail prices and medical procedures
tariffs contracted by National Health Found. Cost-effectiveness
was expressed as cost per cardiovascular event avoided. The time
horizon was the mean study duration of 8 months. All costs are
expressed in EURO and EURO’PPP (1€ = 2.08 PLN’ PPP2003).
RESULTS: Mean direct treatment cost per patient was higher 
in clopidogrel than control group (2700 and 2248€, 5711, and
4759€’PPP, respectively). The observed difference was attribut-
able mostly to a higher acquisition cost of clopidogrel. The mean
cost of initial hospitalizations (including study drug) was reduced
for clopidogrel group by 26€, 57€’PPP. The estimated incremen-
tal cost per event avoided amounted to 12,858€, 27,043€’PPP.
CONCLUSIONS: Treatment with clopidogrel resulted in reduc-
tion of initial hospitalizations costs. The cost per event avoided
with clopidogrel in patients undergoing a PCI is comparable to
other interventions in this area considered as cost-effective.
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OBJECTIVE: to perform cost-effectiveness analysis of alteplase
compared with streptokinase and absence of thrombolytical
therapy for myocardial infarction (MI) in Russia. METHODS:
Data on effectiveness of treatment and resource use were
extracted from hospital medical charts randomly selected from
10 city hospitals in a retrospective study. A total of 133 patients
received alteplase, 97 patients received streptokinase and 131
patients did not receive thrombolytical therapy. Effectiveness was
assessed by death rate, presence of anginal pains, arrhythmia and
heart failure at discharge. Direct medical costs were calculated
on the basis of price-lists for medical services of an insurance
company and median prices for drugs given in a wholesale phar-
maceutical informational bulletin. Incremental cost-effectiveness
ratio (ICER) was calculated for alteplase vs streptokinase and no
thrombolytical therapy and for streptokinase vs no thrombolyt-
ical therapy. RESULTS: There was no signiﬁcant difference in
death rate between 3 groups. Patients from alteplase group sig-
niﬁcantly less often had heart failure by the end of hospital treat-
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ment as well as anginal pains. Rate of arrhythmia at discharge
was minimal in streptokinase group. Alteplase required much
more costs than streptokinase or treatment without thrombolyt-
ical therapy. ICER was 252,454.31 rubles ($7889.20) per
absence of heart failure at discharge for alteplase vs streptoki-
nase, and 166,720.5 rubles ($5210.02) for alteplase vs treatment
without thrombolytical therapy. Still streptokinase was more
cost-effective vs treatment without thrombolytical therapy: ICER
was 4038.76 rubles ($126.21) per absence of heart failure at dis-
charge. CONCLUSION: Alteplase is less cost-effective throm-
bolytical strategy for MI than streptokinase in spite of higher
effectiveness.
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OBJECTIVES: We assessed the long-term cost-effectiveness of
the use of clopidogrel on top of standard therapy (including
aspirin) in comparison with ASA only in patients undergoing
percutaneous coronary interventions in Sweden. METHODS: A
Markov model was developed. Transition probabilities for rele-
vant events were estimated based on RIKS-HIA, a register on
patients treated in the coronary care units at 74 (out of 78) hos-
pitals throughout Sweden. Patients were assumed to be treated
for one year with an effect based on the PCI-CURE trial. Costs
for the intervention and the deﬁned events were collected from
published sources and recalculated to 2003 prices. Life-years
gained were used as the measure of effectiveness, with QALYs
gained as a sensitivity analysis. The perspective was that of the
Swedish society with a separate analysis using a health care cost
perspective. Costs and effects were discounted at 3%. RESULTS:
The model predicts a net gain in survival of 0.04 years when
adding clopidogrel. This comes at a net increased cost of 441€
if only direct costs are included. Including indirect costs, the net
increase is reduced to 326€. The resulting cost-effectiveness ratio
was 10,782€ and 7971€ per life-year gained for the different def-
initions of cost. Assuming a 0.1 reduction in utility following a
MI, the cost per QALY gained was 6381€. Cost-effectiveness
ratios were even lower in diabetics compared to non-diabetics.
Results were robust to changes in discount rate and variations
in unit costs. CONCLUSIONS: The predicted cost-effectiveness
ratios are well below the threshold values generally considered
cost-effective. Adding clopidogrel to ASA thus appears cost-
effective in this indication.
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OBJECTIVES: High density lipoprotein-cholesterol (HDL-C) is
inversely and independently associated with increased risk of car-
diovascular disease (CVD). The importance of HDL-C as a risk
factor for CVD is well accepted. We performed a modelling study
to estimate the incremental cost per additional patient achieving
target HDL-C (≥1mmol/L) when Niaspan (extended release
niacin) is added to stable statin therapy in CVD patients from
the perspective of the National Health Service in the UK.
METHODS: A 3-step probabilistic model was developed. Step
1: population of 10,000 patients with a normal distribution of
lipid proﬁles deﬁned by mean and standard deviation was
created. Step 2: treatment effects of atorvastatin 10mg were
applied to the population and those whose low density lipopro-
tein-cholesterol (LDL-C) was satisfactory (£3.0mmol/L) but did
not reach target HDL-C (≥1.0mmol/L) received treatment with
Niaspan. Step 3: treatment effects of Niaspan were applied in
patients. Baseline lipid values and treatment effects were ran-
domly sampled from distributions drawn from published epi-
demiological and clinical studies using second order Monte
Carlo methodology. Cost for drugs and initiation of Niaspan
treatment were taken from published sources. Results were pre-
sented for the initiation year, taking into account initiation costs
and drop-outs, and maintenance year scenarios. RESULTS: In
total, 16.3% of patients required Niaspan in addition to ator-
vastatin treatment to control dyslipidemia. Of these patients,
29.4% and 36.7% reached target HDL-C after addition of
Niaspan in the initiation and maintenance years respectively.
Additional costs in Niaspan treated patients were £320.30 
and £252.30 for initiation and maintenance years respectively,
leading to incremental costs of £1089 and £687 per additional
patient achieving HDL-C target. CONCLUSIONS: The addi-
tional costs per patient treated to HDL-C target by adding
Niaspan to statin therapy are comparable to those reported in
the literature for treating patients with statins to LDL-C or total
cholesterol targets.
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OBJECTIVES: Little is known about the cost-effectiveness of
secondary prevention after percutaneous coronary intervention
(PCI). Aims of this study are to estimate 1) the cost-effectiveness
of routine ﬂuvastatin therapy after a ﬁrst successful PCI in The
Netherlands, and 2) the chance that ﬂuvastatin therapy is cost-
effective given a society’s willingness to pay as laid down in
Dutch guidelines. METHODS: A cost-effectiveness analysis was
performed using data from the Lescol Intervention Prevention
Study (LIPS). In the LIPS trial, patients with normal blood cho-
lesterol to moderate hypercholesterolemia who had undergone a
ﬁrst PCI were randomized to receive either ﬂuvastatin 40mg
twice-daily plus dietary counseling or dietary counseling alone.
A Markov model (DataPro) was used to estimate the incremen-
tal costs per quality-adjusted life year (QALY) and life year
gained (LYG). Costs were based on prices and reimbursed
charges, utility data were drawn from literature. Hospital costs
(admissions and procedures) were extracted from a database
with complete national coverage. 10,000 Monte Carlo simula-
tions and multivariate analysis were used to assess (2nd order)
uncertainty. RESULTS: The mean net incremental costs of
routine statin treatment were 734€ (SD: 686€) per patient over
10-years compared with controls. Treatment resulted in an incre-
mental 0.078 (0.047) QALYs or 0.082 LYG (0.041). The incre-
mental cost per QALY and LYG were 9312€ (14,648€) and
8954€ (16,617€) respectively. The sensitivity analysis revealed
that the cost of ﬂuvastatin and the discount rate had the largest
effect on the ICER. Anticipating a willingness to pay of 20,000€
per QALY, there is a 75.1% chance that ﬂuvastatin treatment is
cost-effective. CONCLUSIONS: Statin therapy with ﬂuvastatin
